Commentary
“Should we be concerned about the presence of increased portal pressure in non-cirrhotic NAFLD? What would be a safe, easy, and accurate way to detect subclinical portal hypertension and utilise it in risk assessment? How could an early rise in portal pressure contribute to NAFLD pathophysiology and could these mechanisms identify novel therapeutic targets?”
This article by G. Baffy (Harvard Medical School, USA) and J. Bosch (University of Bern, Switzerland, and University of Barcelona, Spain) is a review of recent advances on these controversial issues.
